The FDA has approved Teva’s generic version of Novo Nordisk's Saxenda (liraglutide), marking the first generic GLP-1 therapy for weight loss in the U.S. The product is indicated for adults with obesity or overweight with weight-related conditions, as well as pediatric patients aged 12 and older weighing at least 132 lbs (60 kg).
In December 2024, Teva also secured FDA approval for a generic version of Victoza, Novo Nordisk’s other liraglutide brand indicated for type 2 diabetes. Novo Nordisk manufactures Teva’s generic liraglutide for diabetes, and if they also produce Teva’s version for obesity, it will not be a surprise.
Obesity drugs are projected to grow from $13.8 billion in 2024 to nearly $49 billion by 2030, and success will depend not only on next-generation therapies but also on access, affordability, and the availability of generic alternatives.
Sources
